Peptide-analogues of the A and B families of silkmoth chorion proteins form amyloid fibrils under a variety of conditions [Iconomidou, V.A., Vriend, G. Hamodrakas, S.J. 2000. Amyloids protect the silkmoth oocyte and embryo. FEBS Lett. 479, 141-145; Iconomidou,V.A., Chryssikos, G.D.,Gionis, V., Vriend, G., Hoenger, A., Hamodrakas, S.J., 2001. Amyloid-like fibrils from an 18-residue peptide-analo...

We report the results of solid-state nuclear magnetic resonance (NMR) and atomic force microscopy measurements on amyloid fibrils formed by residues 10-39 of the yeast prion protein Ure2p (Ure2p(10)(-)(39)). Measurements of intermolecular (13)C-(13)C nuclear magnetic dipole-dipole couplings indicate that Ure2p(10)(-)(39) fibrils contain in-register parallel beta-sheets. Measurements of intermol...

Amyloidosis is a generic term for a heterogeneous group of disorders associated with deposition of protein in an abnormal fibrillar form. The diverse spectrum of amyloid related diseases is now recognised to include Alzheimer’s disease, type II diabetes, and the transmissible spongiform encephalopathies. Amyloidosis can be hereditary or acquired, localised or systemic, and potentially lethal or...

The protein β2-microglobulin can aggregate in insoluble amyloid fibrils. By relying on extensive sampling simulations, we study the Pro32 isomerization as a possible triggering factor leading to structural modifications β2-m.

Myostatin, a negative regulator of muscle growth, has been implicated in sporadic inclusion body myositis (sIBM). sIBM is the most common age-related muscle-wastage disease with a pathogenesis similar to that of amyloid disorders such as Alzheimer's and Parkinson's diseases. Myostatin precursor protein (MstnPP) has been shown to associate with large molecular weight filamentous inclusions conta...

We have previously reported studies of fibril formation by a set of protein G B1 domain (beta1) variants, with mutations located around the central parallel beta-strands. In this study, we designed multiple mutations in the edge strands of beta1 to create proteins with a stability range comparable to that of the set of central mutants. All the edge variants are able to form amyloid fibrils when...

Background & Aims: Many neurodegenerative diseases including Alzheimer’s, Parkinson and Huntington diseases are associated with the deposition proteinaceous aggregates known as amyloid fibrils. Currently, there is no approved therapeutic agent for inhibition of fibrillar assemblies. One important approach in the development of therapeutic agents is the use of herbal extracts. At the present com...